Gastro-resistant Controlled Release Dosage Form for QT Prolongation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of roluperidone hydrochloride (MIN-101) lead to QT prolongation due to high plasma levels of Compound (I) and its metabolite BFB-520, necessitating a formulation that reduces QT prolongation risk while maintaining therapeutic efficacy.
Innovation Solution
A gastro-resistant, controlled release dosage form containing 2-200 mg of Compound (I) with controlled release agents, designed to minimize initial release and achieve a plasma pharmacokinetic profile with Tmax between 4-22 hours, reducing BFB-520 levels below 80 ng/mL and maintaining effective Compound (I) levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If a standard release formulation of Compound (I) is used, then rapid drug absorption occurs, but QT prolongation risk increases due to high plasma levels of Compound (I) and BFB-520
Solution Approach 1:
The patent applies dynamic release control by using pH-dependent enteric coating materials (e.g., Eudragit L100, Eudragit S100) that change their permeability properties in response to pH changes along the GI tract. The coating remains intact in acidic stomach environment (pH 1.2-3.0) preventing release, then dissolves and releases drug in intestinal environment (pH 6.8-7.5), creating a dynamic, adaptive release profile that minimizes Cmax while maintaining therapeutic levels
Solution Approach 2:
The patent changes the release parameter by controlling drug dissolution through pH conditions. The enteric coating is designed to withstand gastric pH (1.2-3.0) without dissolving, then dissolves at intestinal pH (6.8-7.5), transforming the release behavior from immediate to delayed. This parameter change (pH-triggered dissolution) directly reduces plasma Cmax and BFB-520 levels, eliminating QT prolongation risk while maintaining AUC and therapeutic efficacy
2Object-affected harmful factors
If a controlled release formulation is used to reduce plasma Cmax, then QT prolongation risk decreases, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent applies preliminary protection by pre-coating the drug core with enteric materials before administration. This preliminary action ensures the drug is protected from gastric dissolution and only releases in the intestine, where pH conditions trigger controlled dissolution. The preliminary enteric coating action prevents harmful rapid absorption while ensuring subsequent reliable therapeutic levels are achieved in the target intestinal environment
Solution Approach 2:
The patent uses the intestinal environment (specifically pH 6.8-7.5 conditions) as an intermediary trigger for drug release. The enteric coating acts as a mediator that remains stable in the stomach but dissolves in the intestine, using the pH difference as an intermediary signal to control release timing. This intermediary mechanism ensures drug is released only when therapeutic conditions are optimal, maintaining efficacy while reducing toxicity
3Quantity of substance
If the drug is released quickly in the stomach, then bioavailability is high, but BFB-520 metabolite levels increase causing QT prolongation
Solution Approach 1:
The patent segments the GI tract environment into distinct zones (stomach vs. intestine) and targets drug release to a specific segment (intestine). The enteric coating creates a spatial segmentation effect, preventing drug release in the stomach (pH 1.2-3.0) while enabling release in the intestine (pH 6.8-7.5). This spatial segmentation ensures drug is released only in the intestinal segment, avoiding gastric absorption that leads to high BFB-520 levels and QT prolongation, while maintaining overall bioavailability
Data Source
AI summary
This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I):or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.